Corrigendum to the summary of Community decisions on marketing authorizations in respect of medicinal products from 1 December 2007 to 31 December 2007 (Official Journal of the European Union C 19 of 25 January 2008) 2012/C 107/08
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/corrigendum/oj/C/2012/107/08@2012-04-13/en
Contents
On page 4, third and fourth rows of the table: for: 12.12.2007 Olanzapine Teva Olanzapine Teva Pharma B.V. Computerweg 10 3542 DR Utrecht Nederland EU/1/07/427/001-022 Film-coated tablet N05AH03 14.12.2008 EU/1/07/427023-037 Orodispersible tablets 13.12.2007 Atripla Efavirenz/emtricitabine/tenofovir disoproxil fumarate Bristol-Myers Squibb Gilead Sciences And Merck Sharp & Dohme Limited Unit 13 Stillorgan Industrial Park Blackrock, Co.Dublin Ireland EU/1/07/430/001 Film-coated tablet J05AR06 18.12.2008 read: 12.12.2007 Olanzapine Teva Olanzapine Teva Pharma B.V. Computerweg 10 3542 DR Utrecht Nederland EU/1/07/427/001-022 Film-coated tablet N05AH03 14.12.2007 EU/1/07/427023-037 Orodispersible tablets 13.12.2007 Atripla Efavirenz/emtricitabine/tenofovir disoproxil fumarate Bristol-Myers Squibb Gilead Sciences And Merck Sharp & Dohme Limited Unit 13 Stillorgan Industrial Park Blackrock, Co. Dublin Ireland EU/1/07/430/001 Film-coated tablet J05AR06 18.12.2007